Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?

JAMA. 2023 Aug 8;330(6):510-511. doi: 10.1001/jama.2023.11704.

Authors

Jennifer J Manly¹, Kacie D Deters²

Affiliations

¹ Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Irving Medical Center, New York, New York.
² Department of Integrative Biology and Physiology, University of California, Los Angeles.

PMID: 37459138
DOI: 10.1001/jama.2023.11704

No abstract available

Publication types

Editorial
Comment

MeSH terms

Alzheimer Disease* / drug therapy
Antibodies, Monoclonal
Humans
Risk Factors
Self-Injurious Behavior*

Substances

Antibodies, Monoclonal